Related Experiment Videos
Primary pulmonary sporotrichosis
The American Review of Respiratory Disease
|June 1, 1977
Summary
A 34-year-old presented with a slow-progressing cavitary pulmonary sporotrichosis. Successful treatment involved surgery and amphotericin B, with no relapse during follow-up.
Area of Science:
- Medical Mycology
- Pulmonary Medicine
- Toxicology
Background:
- Sporothrix schenckii is a fungus that can cause sporotrichosis, a disease that affects the skin, lungs, and other tissues.
- Pulmonary sporotrichosis is a rare form of the disease that primarily affects the lungs and can be difficult to treat.
- Intravenous drug abuse is a known risk factor for various infections, including fungal infections.
Observation:
- A 34-year-old individual with a history of alcoholism and intravenous drug abuse developed cavitary pulmonary sporotrichosis.
- The condition progressed slowly over a 6-year period.
- Histological examination revealed granulomatous inflammation with Sporothrix schenckii and interstitial talc (magnesium silicate) granulomas.
Findings:
- Surgical resection combined with amphotericin B therapy led to prompt clinical improvement.
- A 2-year follow-up showed no evidence of disease relapse.
- The presence of talc granulomas, linked to intravenous drug use, was noted, though its specific role in the sporotrichosis pathogenesis remains unclear.
Implications:
- This case highlights the potential for slow progression of pulmonary sporotrichosis in immunocompromised individuals.
- Aggressive treatment including surgical intervention and antifungal therapy can be effective.
- The co-occurrence of talc granulomas suggests a potential interaction between inhaled/injected substances and fungal infections, warranting further investigation.